13

LATEST Ppt - Wockhardt

Embed Size (px)

Citation preview

Page 1: LATEST Ppt - Wockhardt
Page 2: LATEST Ppt - Wockhardt

-

INTRODUCTION

A pharmaceutical and biotechnology company headquartered in Mumbai, India.

- Manufacturing plants in India, UK, Ireland, France and US.

-Subsidiaries in US, UK, Ireland and France.

-Founded by Habil Khorakiwala in the early 1960s.

- First company outside of the US and Europe to manufacture recombinant human insulin.

Page 3: LATEST Ppt - Wockhardt

SWOT ANALYSIS

STRENGTHS

• Strong expertise in the area of Recombinant Biotechnology

• Strong presence in the European market (50%+ revenue comes from Europe)

• Significant ramping up of the US business (with a growth of 50%)

• Robust manufacturing infrastructure• Strong insulin portfolio in India

Page 4: LATEST Ppt - Wockhardt

WEAKNESSES

• Less contribution towards revenues by the US business

• High debt burden

Page 5: LATEST Ppt - Wockhardt

OPPORTUNITIES• Leverage on synergies present in the European

market

• Launch of Glaritus

Page 6: LATEST Ppt - Wockhardt

THREATS

• Integration of European businesses is a major challenge (Negma and Pinewood acquisitions have to be integrated with the UK business)

• Pricing pressure in the US may restrict expected revenue growth (price erosion more than 95%) specially in cephalosporin segment, with growing competition from companies like Orchid Chemicals and Lupin

• High competition for EPO in regulated markets• Increasing competition in the European generic market

with the growing presence of frontline Indian pharma companies including Ranbaxy and Reddys

Page 7: LATEST Ppt - Wockhardt

MARKET

• Annual turnover of US$ 650 million, and a market capitalisation of over $ 1 billion.

• Wockhardt has revenue of Rs 4,501 crore and operating profit (EBIDTA) at Rs 823 crore during the 15 months period (Jan 2009 – Mar 2010).

• For the quarter (Jan-March 2010) , the sales revenue was Rs 872 crore and operating profit (EBITDA) was Rs 158 crore.

Page 8: LATEST Ppt - Wockhardt

GROWTH

• India Business: Wockhardt’s India branded business grew by 24% in Jan-Mar 2010 over the corresponding period of 2009.

• Europe Business: Wockhardt UK grew by 19% compared to the industry growth of only 5% in Jan-Mar 2010 over the corresponding period of 2009.

• USA Business: Wockhardt`s Morton Grove Pharmaceuticals business has shown a robust 40% growth in Jan-Mar 2010 over the corresponding period of 2009.

Page 9: LATEST Ppt - Wockhardt

TOP PRODUCTS

DIABETOLOGY NEPHROLOGY Wosulin (Recombinant Insulin ) Wepox (Recombinant Mopaday (Oral Antidiabetic) Erythropoietin)Glimaday (Oral Antidiabetic)

PAIN MANAGEMENT: NUTRITION Proxyvon Methycobal

DexolacNEURO-PSYCHIATRY

Spasmo-Proxyvon

NEURO-PSYCHIATRY COUGH THERAPY Libotryp Zedex Tryptomer Bro-Zedex

Viscodyne

Page 10: LATEST Ppt - Wockhardt

PRODUCT-WISE VALUES PRODUCTS Value in Crores % +/- %

Spasmo-Proxyvon 89.41 0.21 7.4

Dexolac 61.99 0.14 26.9

Bro-Zedex 30.38 0.07 36.9

Magenta 30.31 0.07 -1.9

Zedex 28.27 0.07 41

Proxyvon 24.2 0.06 21.4

Merideca 23.5 0.05 -17.5

Wokadine 23.47 0.05 36.8

Page 11: LATEST Ppt - Wockhardt

NEW LAUNCHES

• Insulin Glaritus• Tamsulosin capsules(Flomax)• Amoxicillin Clav K OS,• Azithromycin Tablets, • Divalproex Extended Release Tablets• Midazolam HCI Injection, • Nicardipine Injection, • Ranitidine Tablets,• Risperidone Tablets, • Ropinirole HCI Tablets

Page 12: LATEST Ppt - Wockhardt

TOP COMPETITORS

• Aurobindo Pharma Limited• Cipla Limited• Glaxo Smithkline Pharmaceuticals

Limited• Dr. Reddy's Laboratories Limited• Ranbaxy Laboratories Limited

Page 13: LATEST Ppt - Wockhardt